Patricia T Richards

8222267, Jul 17, 2012

Jul 18, 2011

13/185016

Patricia T. Richards - West New York NJ, US
Warren C. Stern - Plymouth MA, US
Benjamin Schwartz - St. Louis MO, US

QRxPharma Ltd. - North Sydney

A01N 43/42
A01N 43/38
A01N 37/10
A61K 31/44
A61K 31/40
A61K 31/19
A61K 9/28
A61K 9/20
C07D 489/00

514282, 546 44, 514420, 514568, 424474, 424468

A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents, a one-hour average oral morphine equivalents, or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.

20090291975, Nov 26, 2009

May 20, 2009

12/469438

WARREN STERN - Plymouth MA, US
Gary W. Pace - La Jolls CA, US
Felix A. de la IgLesia - Ann Arbor MI, US
Maree Smith - Bardon, AU
Patricia Richards - West New York NJ, US

A61K 31/485
A61P 29/00

514282

Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with optimal ratios of morphine and oxycodone that provide superior analgesic efficacy and lower incidence of adverse side effects compared to morphine and oxycodone alone. The pharmaceutical compositions comprise morphine and oxycodone, or pharmaceutically acceptable salts thereof, in ratios of about 3 to 2 to about 1 to 2, morphine to oxycodone by weight.

20110046173, Feb 24, 2011

Sep 25, 2009

12/567209

Warren Charles Stern - Plymouth MA, US
Patricia Tewes Richards - West New York NJ, US

A61K 31/485

514282

Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with ratios of morphine and oxycodone that provide lower incidence of adverse side effects compared to equi-analgesic doses of morphine and oxycodone alone. The pharmaceutical compositions comprise an analgesic amount of morphine and an analgesic amount of oxycodone, or pharmaceutically acceptable salts thereof, in ratios of about 3 to 2 to about 1.25 to 1, morphine to oxycodone by weight.

20120283283, Nov 8, 2012

May 4, 2012

13/464025

Warren C. Stern - Plymouth MA, US
Patricia T. Richards - West New York NJ, US

G01N 33/50
A61P 25/00
A61K 31/485

514282, 436 68

Methods for detecting enhanced risk of opioid-induced respiratory dysfunction in patients with normal levels of oxygen saturation. The method may comprise: (1) assaying blood of the patient for a normal level of oxygen saturation; (2) measuring the patient's respiration rate at rest for a normal rate; and (3) correlating the normal level of oxygen saturation and the normal rate of respiration with enhanced risk of opioid-induced respiratory dysfunction if: (a) the patient is at an altitude of about 1000 feet above sea level or greater; or (b) the patient's oxygen saturation level is normal but no greater than about 95%; or (c) the patient received prior dosing with intravenous opioid and is converted to dosing with an oral opioid. The method may further comprise administering opioids to a patient after detecting whether there is an enhanced risk of opioid-induced respiratory dysfunction.